The Role of Iron and Chelators on Infections in Iron Overload and Non Iron Loaded Conditions: Prospects for the Design of New Antimicrobial Therapies

REFERENCES

• Neilands JB Siderophores: structure and function of microbial iron transport compounds. J Biol Chem. 1995;270(45):26723–26726.
   PubMed Web of Science ®Google Scholar
• Weinberg ED. Iron depletion: a defense against intracellular infection and neoplasm. Life Sci. 1992;50(18):1289–1297.
   PubMedGoogle Scholar
• Akers HA, Abrego VA, Garland E. Thujaplicins from Thuja plicata as iron transport agents for Salmonella typhimurium. J Bacteriol. 1980;141(1):164–168.
   PubMedGoogle Scholar
• Kontoghiorghes GJ. The design of orally active iron chelators for the treatment of thalassaemia. Doctoral thesis, University of Essex, Colchester, UK. British Library Microfilm No. D66194/86. 1982:1–243.
   Google Scholar
• Djaldetti M, Fishman P, Notti I, Bessler H. The effect of tetracycline administration on iron absorption in mice. Biomedicine. 1981;35(5):150–152.
   PubMedGoogle Scholar
• Kontoghiorghes GJ, Weinberg ED. Iron: mammalian defense systems, mechanisms of disease and chelation therapy approaches. Blood Rev. 1995;9(1):33–46.
   PubMed Web of Science ®Google Scholar
• Zurlo MG, De Stefano P, Borgna-Pignatti C, Survival and causes of death in thalassaemia major. Lancet. 1989;2(8653):27–30.
   PubMed Web of Science ®Google Scholar
• Borgna-Pignatti C, Rugolotto S, De Stefano P, Survival and disease complications in thalassemia major. Ann NY Acad Sci. 1998;850:227–231.
   PubMed Web of Science ®Google Scholar
• Wanachiwanawin W. Infections in E-β thalassemia. J Pediatr Hematol Oncol. 2000;22(6):581–587.
   PubMedGoogle Scholar
• Kolnagou A, Economides Ch, Eracleous E, Kontoghiorghes GJ. Long term comparative studies in thalassemia patients treated with deferoxamine or a deferoxamine/deferiprone combination. Identification of effective chelation therapy protocols. Hemoglobin. 2008;32(1-2):41–47.
   PubMed Web of Science ®Google Scholar
• Harrison P, Marwah SS, Hughes RT, Bareford DJ. Non-transferrin bound iron and neutropenia after cytotoxic chemotherapy. J Clin Pathol. 1994;47(4):350–352.
   PubMedGoogle Scholar
• Walker EM Jr, Walker SM. Effects of iron overload on the immune system. Ann Clin Lab Sci. 2000;30(4):354–365.
   PubMed Web of Science ®Google Scholar
• Kontoghiorghes GJ, Eracleous E, Economides Ch, Kolnagou A. Advances in iron overload therapies. Prospects for effective use of deferiprone (L1), deferoxamine, the new experimental chelators ICL670, GT56–252, L1NAll and their combinations. Curr Med Chem. 2005;12(23):2663–2681.
   PubMed Web of Science ®Google Scholar
• Robins-Browne RM, Pipic JK. Desferrioxamine and systemic yersiniosis. Lancet. 1983;II(8363):1372.
   Google Scholar
• Brock JH, Liceaga J, Kontoghiotghes GJ. The effect of synthetic iron chelators on bacterial growth in human serum. FEMS Microbiol Immunol. 1988;47:55–60.
   Google Scholar
• Boelaert JR, Fenves AZ, Coburn JW. Deferoxamine therapy and mucormycosis in dialysis patients: report of an international registry. Am J Kidney Dis. 1991;18(6):660–667.
   PubMed Web of Science ®Google Scholar
• Gordeuk VR, Thuma PE, Brittenham GM, Iron chelation with desferrioxamine B in adults with asymptomatic P. Falciparum parasitemia. Blood. 1992;79(2):308–312.
   PubMedGoogle Scholar
• Moreau-Marquis S, O'Toole GA, Stanton BA. Tobramycin and FDA-approved iron chelators eliminate Pseudomonas aeruginosa biofilms on cystic fibrosis cells. Am J Respir Cell Mol Biol. 2009;41(3)305–313.
   PubMed Web of Science ®Google Scholar
• Ibrahim AS, Gebermariam T, Fu Y, The iron chelator deferasirox protects mice from mucormycosis through iron starvation. J Clin Invest. 2007;117(9):2650–2657.
   Google Scholar
• Spellberg B, Andes D, Perez M, Safety and outcomes of open-label deferasirox iron chelation therapy for mucormycosis. Antimicrob Agents Chemother. 2009;53(7):3122–3125.
   PubMed Web of Science ®Google Scholar
• Douvas GS, May MH, Kolnagou A, Kontoghiorghes GJ. Effects on Mycobacterium avium replication in normal human macrophages by deferiprone (L1) and other iron chelators. Possible implications on toxicity. Arzneimittelforschung. 2002;52(1):45–52.
   PubMedGoogle Scholar
• Zarember KA, Cruz AR, Huang CY, Gallin JI. Antifungal activities of natural and synthetic iron chelators alone and in combination with azole and polyene antibiotics against Aspergillus fumigatus. Antimicrob Agents Chemother. 2009;53(6):2654–2656.
   PubMed Web of Science ®Google Scholar
• Jones MM, Singh PK, Lane JE, Inhibition of Trypanosoma cruzi epimastigotes in vitro by iron chelating agents. Arzneimittelforschung. 1996;46(12):1158–1162.
   PubMedGoogle Scholar
• Soteriadou K, Papavassiliou P, Voyiatzaki C, Boelaert J. Effect of iron chelation on the in-vitro growth of Leishmania promastigotes. J Antimicrob Chemother. 1995;35(1):23–29.
   PubMedGoogle Scholar
• Kim CM, Shin SH. Effect of iron-chelator deferiprone on the in vitro growth of staphylococci. J Korean Med Sci. 2009; 24(2):289–295.
   PubMedGoogle Scholar
• Neupane GP, Kim DM. Comparison of the effects of deferasirox, deferiprone, and deferoxamine on the growth and virulence of Vibrio vulnificus. Transfusion. In press.
   Google Scholar
• Ibrahim AS, Edwards JE Jr, Fu Y, Spellberg B. Deferiprone iron chelation as a novel therapy for experimental mucormycosis. J Antimicrob Chemother. 2006;58(5):1070–1073.
   PubMed Web of Science ®Google Scholar
• Mastrandrea S, Carvajal JL, Kaeda JS, Kontoghiorghes GJ, Luzzato L. Growth inhibition of Plasmodium Falciparum by orally active iron chelators. Drugs Today. 1992;28(Suppl A):25–27.
   Google Scholar
• Heppner DG, Hallaway PE, Kontoghiorghes GJ, Eaton JW. Antimalarial properties of orally active iron chelators. Blood. 1988;72(1):358–361.
   PubMedGoogle Scholar
• Thuma PE, Olivieri NF, Mabeza GF, Assessment of the effect of the oral iron chelator deferiprone on asymptomatic Plasmodium falciparum parasitaemia in humans. Am J Trop Med Hyg. 1998;58(3):358–364.
   PubMedGoogle Scholar
• Mohanty D, Ghosh K, Pathare AV, Kanrad D. Deferiprone (L1) as an adjuvant therapy for Plasmodium falciparum malaria. Indian J Med Res. 2002;115:17–21.
   PubMed Web of Science ®Google Scholar
• Tanner MA, Galanello R, Dessi C, A randomised, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance. Circulation. 2007;115(14):1876–1884.
   PubMed Web of Science ®Google Scholar
• Kontoghiorghes GJ, Neocleous K, Kolnagou A. Benefits and risks of deferiprone in iron overload in thalassemia and other conditions. Comparison of epidemiological and therapeutic aspects with deferoxamine. Drug Saf. 2003; 26(8):553–584.
   PubMed Web of Science ®Google Scholar
• Boddaert N, Le Quan Sang KH, Rotig A, Selective iron chelation in Friedreich ataxia: biologic and clinical implications. Blood. 2007;110(1):401–408.
   PubMed Web of Science ®Google Scholar
• Rajapurkar MM, Alam MG, Bhattacharya A, Shah S. Novel treatment for diabetic nephropathy. J Am Soc Nephrol. 2007;18:329A.
   Google Scholar
• Rajapurkar MM, Beliga R, Shah S. Treatment of patients with glomerulonephritis with an oral iron chelator. J Am Soc Nephrol. 2007;18:57A–58A.
   Google Scholar
• Forni GL, Balocco M, Cremonesi L, Abbruzzese G, Parodi RC, Marchese R. Regression of symptoms after selective iron chelation therapy in a case of neurodegeneration with brain iron accumulation. Mov Disord. 2008;23(6):904–907.
   PubMed Web of Science ®Google Scholar
• Weinberg ED. Iron availability and infection. Biochim Biophys Acta. 2009:1790(7):600–605.
   PubMed Web of Science ®Google Scholar
• Brock JH, Liceaga J, Arthur HM, Kontoghiorghes GJ. Effect of novel 1-alkyl-3-hydroxy-2-methylpyrid-4-one chelators on uptake and release of iron from macrophages. Am J Hematol. 1990;34(1):21–25.
   PubMedGoogle Scholar